Cargando…

Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial

BACKGROUND: Despite major advances in transplant medicine, improvements in long-term kidney allograft survival have not been commensurate with those observed shortly after transplantation. The formation of donor-specific antibodies (DSA) and ongoing antibody-mediated rejection (AMR) processes may cr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eskandary, Farsad, Bond, Gregor, Schwaiger, Elisabeth, Kikic, Zeljko, Winzer, Christine, Wahrmann, Markus, Marinova, Lena, Haslacher, Helmuth, Regele, Heinz, Oberbauer, Rainer, Böhmig, Georg A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014747/ https://www.ncbi.nlm.nih.gov/pubmed/24708575 http://dx.doi.org/10.1186/1745-6215-15-107

Ejemplares similares

Non-invasive Chemokine Detection: Improved Prediction of Antibody-Mediated Rejection in Donor-Specific Antibody-Positive Renal Allograft Recipients
por: Mühlbacher, Jakob, et al.
Publicado: (2020)

Early Estimated Glomerular Filtration Rate Trajectories After Kidney Transplant Biopsy as a Surrogate Endpoint for Graft Survival in Late Antibody-Mediated Rejection
por: Borski, Anita, et al.
Publicado: (2022)

Complement Markers in Blood and Urine: No Diagnostic Value in Late Silent Antibody-Mediated Rejection
por: Mező, Blanka, et al.
Publicado: (2019)

Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial
por: Eskandary, Farsad, et al.
Publicado: (2019)

Torque teno virus for risk stratification of graft rejection and infection in kidney transplant recipients—A prospective observational trial
por: Doberer, Konstantin, et al.
Publicado: (2020)

The therapeutic challenge of late antibody‐mediated kidney allograft rejection
por: Böhmig, Georg A., et al.
Publicado: (2019)

Diagnostic value of donor‐derived cell‐free DNA to predict antibody‐mediated rejection in donor‐specific antibody‐positive renal allograft recipients
por: Mayer, Katharina A., et al.
Publicado: (2021)

High-activity Classical and Alternative Complement Pathway Genotypes—Association With Donor-specific Antibody-triggered Injury and Renal Allograft Survival
por: Mező, Blanka, et al.
Publicado: (2020)

Stopping of Mycophenolic Acid in Kidney Transplant Recipients for 2 Weeks Peri-Vaccination Does Not Increase Response to SARS-CoV-2 Vaccination—A Non-randomized, Controlled Pilot Study
por: Regele, Florina, et al.
Publicado: (2022)

Torque Teno Virus for Risk Stratification of Acute Biopsy-Proven Alloreactivity in Kidney Transplant Recipients
por: Strassl, Robert, et al.
Publicado: (2019)

Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial
por: Mayer, Katharina A., et al.
Publicado: (2022)

Torque Teno Virus Load Is Associated With Subclinical Alloreactivity in Kidney Transplant Recipients: A Prospective Observational Trial
por: Doberer, Konstantin, et al.
Publicado: (2021)

Longitudinal assessment of HLA and MIC-A antibodies in uneventful pregnancies and pregnancies complicated by preeclampsia or gestational diabetes
por: Küssel, Lorenz, et al.
Publicado: (2017)

Quantification of Torque Teno Virus Viremia as a Prospective Biomarker for Infectious Disease in Kidney Allograft Recipients
por: Strassl, Robert, et al.
Publicado: (2018)

Effect of the Anti‐C1s Humanized Antibody TNT009 and Its Parental Mouse Variant TNT003 on HLA Antibody–Induced Complement Activation—A Preclinical In Vitro Study
por: Wahrmann, M., et al.
Publicado: (2017)

ABO-Incompatibility: Time to Challenge the Paradigm of Equivalence in Live-Donor Kidney Transplantation?
por: Eskandary, Farsad, et al.
Publicado: (2022)

Renal allograft DARCness in subclinical acute and chronic active ABMR
por: Kläger, Johannes, et al.
Publicado: (2021)

Magnetic Resonance Imaging for Evaluation of Interstitial Fibrosis in Kidney Allografts
por: Beck-Tölly, Andrea, et al.
Publicado: (2020)

Functional Fc Gamma Receptor Gene Polymorphisms and Long-Term Kidney Allograft Survival
por: Wahrmann, Markus, et al.
Publicado: (2021)

Anti‐interleukin‐6 antibody clazakizumab in late antibody‐mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism
por: Mühlbacher, Jakob, et al.
Publicado: (2021)

Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009—Results from a Randomized First-in-Human Phase 1 Trial
por: Mühlbacher, Jakob, et al.
Publicado: (2017)

Relating Molecular T Cell–mediated Rejection Activity in Kidney Transplant Biopsies to Time and to Histologic Tubulitis and Atrophy-fibrosis
por: Madill-Thomsen, Katelynn S., et al.
Publicado: (2023)

Levels of donor‐derived cell‐free DNA and chemokines in BK polyomavirus‐associated nephropathy
por: Mayer, Katharina A., et al.
Publicado: (2022)

COVID-19 und Nierentransplantation
por: Regele, Florina, et al.
Publicado: (2021)

Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Kidney Transplant Rejection: Effect on Donor-derived Cell-free DNA and C-X-C Motif Chemokine Ligand 10
por: Mayer, Katharina A., et al.
Publicado: (2022)

Glomerular C4d in Post-Transplant IgA Nephropathy is associated with decreased allograft survival
por: Eder, Michael, et al.
Publicado: (2020)

Alloimmune Risk Stratification for Kidney Transplant Rejection
por: Bestard, Oriol, et al.
Publicado: (2022)

Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial
por: Reindl-Schwaighofer, Roman, et al.
Publicado: (2021)

Clinical Relevance of Absolute BK Polyoma Viral Load Kinetics in Patients With Biopsy Proven BK Polyomavirus Associated Nephropathy
por: Omić, Haris, et al.
Publicado: (2022)

Deletion of the Natural Killer Cell Receptor NKG2C Encoding KLR2C Gene and Kidney Transplant Outcome
por: Vietzen, Hannes, et al.
Publicado: (2022)

The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation
por: Lee, Juhan, et al.
Publicado: (2015)

Next generation sequencing based assessment of the alloreactive T cell receptor repertoire in kidney transplant patients during rejection: a prospective cohort study
por: Aschauer, Constantin, et al.
Publicado: (2019)

ACE2 Elevation in Severe COVID-19
por: Reindl-Schwaighofer, Roman, et al.
Publicado: (2021)

Proposed Definitions of T Cell-Mediated Rejection and Tubulointerstitial Inflammation as Clinical Trial Endpoints in Kidney Transplantation
por: Seron, Daniel, et al.
Publicado: (2022)

Proposed Definitions of Antibody-Mediated Rejection for Use as a Clinical Trial Endpoint in Kidney Transplantation
por: Roufosse, Candice, et al.
Publicado: (2022)

Prospective Tracking of Donor-Reactive T-Cell Clones in the Circulation and Rejecting Human Kidney Allografts
por: Aschauer, Constantin, et al.
Publicado: (2021)

Bortezomib alleviates antibody‐mediated rejection in kidney transplantation by facilitating Atg5 expression
por: Cheng, Hong, et al.
Publicado: (2021)

Markers of potassium homeostasis in salt losing tubulopathies- associations with hyperaldosteronism and hypomagnesemia
por: Eder, Michael, et al.
Publicado: (2020)

Bortezomib: A New Promising Therapy for Early Antibody-Mediated Rejection After Liver Transplantation?
por: Chedid, Marcio F., et al.
Publicado: (2019)

Archetypal Analysis of Injury in Kidney Transplant Biopsies Identifies Two Classes of Early AKI
por: Halloran, Philip F., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v2agd8n526gr74abqevr784oqf